Madrigal Pharmaceuticals, Inc. (NasdaqGS: MDGL)
Health Care · Biotechnology · US
$517.00
+0.95% today · +20.5% 1Y
Madrigal Pharmaceuticals, Inc. (NasdaqGS: MDGL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.83B and employs 915 people.
Over the last twelve months the share price has gained 20.5%, trading between 393.61 and 615.00.
Tweenvest scores Madrigal Pharmaceuticals, Inc. across four factors: quality 38/100, value 84/100. Its strongest factor is value.
MDGL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.83B
- Revenue (TTM)
- $1.28B
- P/E
- —
- EPS
- -14.22
- Dividend yield
- —
- Beta (5Y)
- -1.00
- 52-week high
- $615.00
- 52-week low
- $393.61
- Avg volume (3M)
- —
- Shares outstanding
- 23.10M
- Employees
- 915
- Next earnings
- —
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- ISIN
- US5588681057
- Founded
- 2016
- Listed since
- Feb 6, 2007
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.00 | +0.40% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.